Benzinga's Top #PreMarket Gainers

Exelixis

shares gained 12.78% to $3.75 in pre-market trading after the company reported that coBRIM has met primary endpoint in phase 3 trial. Progenics Pharmaceuticals

shares surged 11.08% to $4.71 in pre-market trading. Salix Pharmaceuticals

and Progenics reported that the FDA Office of Drug Evaluation III has approved Salix request for the FDA approval of RELISTOR sNDA. URS

shares jumped 7.92% to $56.14 in pre-market trading after Aecom Technology

announced its plans to buying URS for $4 billion in cash and stock. Mylan

shares gained 3.59% to $52.00 in pre-market trading after the company announced its plans to acquire Abbott's

non-U.S. developed markets specialty and branded generics business in a $5.3 billion all-stock transaction.